Pre‐treatment carbohydrate antigen 19‐9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

ConclusionsAmong patients who completed neoadjuvant therapy and surgery, pre‐treatment CA19‐9 obtained at the time of diagnosis was not predictive of overall survival, but normalization of post‐treatment CA19‐9 in response to neoadjuvant therapy was highly prognostic.

Source: HPB: official journal of the International Hepato Pancreat Biliary Association - August 10, 2015 Category: Gastroenterology Authors: Mohammed Aldakkak, Kathleen K. Christians, Ashley N. Krepline, Ben George, Paul S. Ritch, Beth A. Erickson, Fabian M. Johnston, Douglas B. Evans, Susan Tsai Tags: Original Article Source Type: research